1
=
-
Idexx Laboratories Inc
As of May 18, 2026 at 24:05 UTC
Chart
About Idexx Laboratories Inc
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Market Statistics
Trading Metrics
How to Buy IDXX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy IDXX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesIDEXX Laboratories reported strong Q1 2026 results with EPS of $3.47 (beating consensus of $3.41) and sales of $1.14 billion (above consensus of $1.109 billion), driven by higher clinical visits and diagnostic frequency. The company raised its full-year 2026 guidance for both earnings ($14.45-$14.90 vs. previous $14.29-$14.80) and sales ($4.675-$4.76 billion vs. previous $4.63-$4.72 billion). Shares were up 3.35% in premarket trading.
The global veterinary reference laboratory market is projected to grow from USD 6.12 billion in 2025 to USD 13.93 billion by 2035, driven by rising pet ownership, pet humanization trends, and increased demand for advanced diagnostics. However, high infrastructure costs and shortage of skilled specialists pose challenges to market expansion.
IDEXX Laboratories reported better-than-expected Q4 2025 earnings of $3.08 per share (beating $2.94 consensus) with $1.091 billion in sales (beating $1.073 billion consensus) and strong growth across segments. The company issued 2026 guidance of $14.29-$14.80 EPS and $4.632-$4.720 billion in sales. Despite the positive results and strong innovation pipeline, IDEXX shares fell 5.57% to $633.10, likely due to guidance slightly below consensus expectations and ongoing end-market visit weakness concerns.
Idexx Laboratories reported strong Q3 2025 financial results, with revenue growing 13% to $1.11 billion and net income rising 18%. The company beat analyst expectations and raised its full-year guidance, leading to a significant stock price increase.
